沙美特罗/福替卡松对中重度慢阻肺患者稳定期的疗效分析

Curative effect analysis of salmeterol/fluticasone in patients with moderate and severe chronic obstructive pulmonary disease in stable phase

目的探讨沙美特罗/福替卡松对中重度慢阻肺患者稳定期的治疗效果。方法选择我院2013年8月至2016年8月收治的1 514例稳定期中重度慢阻肺患者为研究对象,随机分为研究组和对照组,各757例。所有患者均给予抗感染、化痰等基础治疗,对照组患者给予氨茶碱进行治疗,在对照组基础上研究组患者给予沙美特罗/福替卡松进行治疗。比较两组患者的生存质量和治疗效果。结果治疗前,两组患者SGRQ评分比较,差异不显著(P>0.05);治疗后,两组患者SGRQ评分均降低,且研究组患者SGRQ评分显著低于对照组(P<0.05)。研究组患者临床治疗总有效率为96.57%,对照组为87.32%,组间比较,差异显著(P<0.05)。结论沙美特罗/福替卡松治疗稳定期慢阻肺患者可明显改善患者生活质量,提高治疗效果,可推广使用。

Objective To investigate the treatment effect of salmeterol/fluticasone in patients with moderate and severe chronic obstructive pulmonary disease in stable phase. Methods In our hospital from August 2013 to August 2016, 1 514 patients with moderate and severe chronic obstructive pulmonary disease in stable phase were selected as the research objects, which were randomly divided into research group and control group, with 757 cases in each group. All patients were treated with anti-infection, expectorant and other basic treatment, patients in the control group received aminophylline,based on the control group, the patients in the research group were given salmeterol/fluticasone. The quality of life and treatment effects were compared between the two groups. Results There was no significant difference in the SGRQ score between the two groups before treatment（P〉0.05）; after treatment, the SGRQ scores decreased in the two groups, and the SGRQ score of the patients in the research group was significantly lower than that in the control group（P〈0.05）. The clinical total effective rate was 96.57% in the research group and 87.32% in the control group, the difference between the two groups was statistically significant（P〈0.05）. Conclusion Salmeterol/fluticasone in the treatment of moderate and severe chronic obstructive pulmonary disease in stable phase can significantly improve the quality of life of patients and improve the therapeutic effect, which can be widely used.